RNAi-based therapeutics and tumor targeted delivery in cancer

G Kara, GA Calin, B Ozpolat - Advanced drug delivery reviews, 2022 - Elsevier
Over the past decade, non-coding RNA-based therapeutics have proven as a great potential
for the development of targeted therapies for cancer and other diseases. The discovery of …

Advances in the delivery of RNA therapeutics: from concept to clinical reality

JC Kaczmarek, PS Kowalski, DG Anderson - Genome medicine, 2017 - Springer
The rapid expansion of the available genomic data continues to greatly impact biomedical
science and medicine. Fulfilling the clinical potential of genetic discoveries requires the …

RNA-based diagnostic and therapeutic strategies for cardiovascular disease

D Lu, T Thum - Nature Reviews Cardiology, 2019 - nature.com
Cardiovascular diseases are the leading cause of death globally and are associated with
increasing financial expenditure. With the availability of next-generation sequencing …

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches

N Amodio, L Raimondi, G Juli, MA Stamato… - Journal of hematology & …, 2018 - Springer
The deeper understanding of non-coding RNAs has recently changed the dogma of
molecular biology assuming protein-coding genes as unique functional biological effectors …

Chitosan-based nanoparticles against viral infections

H Boroumand, F Badie, S Mazaheri… - Frontiers in Cellular …, 2021 - frontiersin.org
Viral infections, in addition to damaging host cells, can compromise the host immune
system, leading to frequent relapse or long-term persistence. Viruses have the capacity to …

Connective tissue growth factor: from molecular understandings to drug discovery

Z Chen, N Zhang, HY Chu, Y Yu, ZK Zhang… - Frontiers in cell and …, 2020 - frontiersin.org
Connective tissue growth factor (CTGF) is a key signaling and regulatory molecule involved
in different biological processes, such as cell proliferation, angiogenesis, and wound …

Emerging technologies for low‐cost, rapid vaccine manufacture

Z Kis, R Shattock, N Shah… - Biotechnology journal, 2019 - Wiley Online Library
To stop the spread of future epidemics and meet infant vaccination demands in low‐and
middle‐income countries, flexible, rapid and low‐cost vaccine development and …

Emerging delivery approaches for targeted pulmonary fibrosis treatment

R Diwan, HN Bhatt, E Beaven, M Nurunnabi - Advanced drug delivery …, 2024 - Elsevier
Pulmonary fibrosis (PF) is a progressive, and life-threatening interstitial lung disease which
causes scarring in the lung parenchyma and thereby affects architecture and functioning of …

Robust delivery of RIG‐I agonists using extracellular vesicles for anti‐cancer immunotherapy

B Peng, TM Nguyen, MK Jayasinghe… - Journal of …, 2022 - Wiley Online Library
The RIG‐I pathway can be activated by RNA containing 5′ triphosphate, leading to type I
interferon release and immune activation. Hence, RIG‐I agonists have been used to induce …

ADAMTS5 in osteoarthritis: biological functions, regulatory network, and potential targeting therapies

L Jiang, J Lin, S Zhao, J Wu, Y Jin, L Yu… - Frontiers in molecular …, 2021 - frontiersin.org
ADAMTS5 is involved in the pathogenesis of OA. As the major aggrecanase-degrading
articular cartilage matrix, ADAMTS5, has been regarded as a potential target for OA …